Connect with us

TechCrunch

FindAir is a smart inhaler

FindAir is digitizing asthma therapy with smart inhaler technology. The TC Top Picks program showcases outstanding early-stage startups across these categories: AI/Machine Learning, Biotech/Healthtech, Blockchain, Fintech, Mobility, Privacy/Security, Retail/E-commerce, Robotics/IoT/Hardware, SaaS and Social Impact & Education. TechCrunch is a leading technology media property, dedicated to obsessively profiling startups, reviewing new Internet products, and breaking tech…

Published

on

FindAir is digitizing asthma therapy with smart inhaler technology.

The TC Top Picks program showcases outstanding early-stage startups across these categories: AI/Machine Learning, Biotech/Healthtech, Blockchain, Fintech, Mobility, Privacy/Security, Retail/E-commerce, Robotics/IoT/Hardware, SaaS and Social Impact & Education.

TechCrunch is a leading technology media property, dedicated to obsessively profiling startups, reviewing new Internet products, and breaking tech news.

Continue Reading
Advertisement
9 Comments

9 Comments

  1. Abhishek Rao Chimbili

    October 27, 2019 at 4:51 pm

    That is the most useless thing I’ve ever seen.

  2. Brandon S.

    October 27, 2019 at 4:52 pm

    You are supposed to use a spacer. The inhaler alone is not good. Not to mention there are some inhalers that already track the number of uses. This is pointless.

  3. Greg Nulik

    October 27, 2019 at 7:21 pm

    Hope the sensor supports a full dosage.

  4. polyannamoonbeam

    October 27, 2019 at 10:39 pm

    Not enough info …sensor tells you what your trigger was…? How? Blood prick analysis? Heartrate? Allergen analysis? Doctors are now instructed to ration patients to one Ventolin a month, two if you argue at length. There is no science to back up patients self diagnosed need for more, doctors differ on what is sufficient, how to measure severity and are often punitive/ biased against smokers. Many patients become resistant to their Ventolyn due to misuse, long term use.. tracking usage doesnt tell you whether patient needed to use more or less puffs for each event or just misused due to poor technique….severe attacks are not managed by Ventolin. Steroids,adrenalin, intravenous meds, full mask vaporised meds- we use all in winter for son.

  5. Pinitrius

    October 27, 2019 at 11:34 pm

    Being an allergist I was interested to see what this was about… But no! It gives some information about patient adherence to the treatment but as with many products/service it is trying to force a subscription down patients throat without providing real long term value! And the product itself is rendered useless after 12 months due to the non-removable battery!

    To me it is just a gimmick the way they chose to make it and charge for it! Sorry…

  6. TechPimp

    October 28, 2019 at 1:51 am

    I didn’t understand what the heck it does?

  7. Gezaei Teklay

    October 28, 2019 at 2:09 am

    I hope it is helpful for asthma

  8. Arthur

    October 28, 2019 at 9:12 am

    So it counts how many times you use an inhaler a day and displays it on an app?

  9. takeonparis

    October 29, 2019 at 12:15 am

    This is the dumbest interview I’ve ever seen. He doesn’t even bother to ask: “So what does your product DO?” Like what in the actual hell…

Leave a Reply

Your email address will not be published. Required fields are marked *

Science & Technology

Your Q&A Can’t Save a Bad Pitch

Demetri Maxim thought the Q&A was where he could really win investors over. Then he realized: if you lose them during the pitch, they may never ask the questions that let you shine. Hear what Demetri learned from pitching Nephrogen at Startup Battlefield on the latest Build Mode with Dr. Eike Gerhardt.

Published

on

Demetri Maxim thought the Q&A was where he could really win investors over.

Then he realized: if you lose them during the pitch, they may never ask the questions that let you shine.

Hear what Demetri learned from pitching Nephrogen at Startup Battlefield on the latest Build Mode with Dr. Eike Gerhardt.

Continue Reading

Science & Technology

John Ternus Takes Over Apple

Tim Cook had the unenviable job of following Steve Jobs. Now John Ternus has to follow Cook, and he’s taking over an Apple that looks very different from the one Cook inherited. Equity asks what Ternus’ product background could mean for Apple, and how he’ll balance hardware, services, and the company’s push into AI.

Published

on

Tim Cook had the unenviable job of following Steve Jobs. Now John Ternus has to follow Cook, and he’s taking over an Apple that looks very different from the one Cook inherited.

Equity asks what Ternus’ product background could mean for Apple, and how he’ll balance hardware, services, and the company’s push into AI.

Continue Reading

Science & Technology

What will Apple’s John Ternus era look like? | Equity Podcast

It’s officially the Ternus era at Apple. Tim Cook stepped down as CEO this week, handing the company to former hardware chief John Ternus, whose first memo promised a “huge launch next week” — timing that puts Apple’s next iPhone event on his desk before he’s even settled in. Cook isn’t going far, though: he’s…

Published

on

It’s officially the Ternus era at Apple.

Tim Cook stepped down as CEO this week, handing the company to former hardware chief John Ternus, whose first memo promised a “huge launch next week” — timing that puts Apple’s next iPhone event on his desk before he’s even settled in. Cook isn’t going far, though: he’s staying on as executive chairman, focused on the kind of policy relationships that recently turned something as small as a map label into a very public balancing act. All of which raises an obvious question: what does the Ternus era look like, and how much rope will shareholders give him to figure it out?

On this episode of TechCrunch’s Equity podcast, hosts Kirsten Korosec and Sean O’Kane unpack what Ternus is walking into, why he may actually be better positioned to make progress on software than hardware in this new AI era, and more of the week’s news.

Subscribe to Equity on YouTube, Apple Podcasts, Overcast, Spotify and all the casts. You also can follow Equity on X and Threads, at @EquityPod.

Chapters

00:00 Intro

1:12 Tim Cook steps down & John Ternus takes over as CEO

13:33 Nvidia’s spreading its AI bets

21:58 A big week for robotaxis: Tesla, Waymo, Zoox & Uber

29:09 a16z’s $1.1B “machine age” fund and $8.5B growth fund

32:39 GoPro’s $285M acquisition and pivot to AI/defense

36:34 Outro

Continue Reading

Trending